Souhaitez-vous accéder aux communiqués récents ?
Créez un compte lecteur dès aujourd’hui afin de suivre les secteurs et les entreprises qui vous intéressent, et configurer votre tableau de bord.
-
DaltonTx launches its drug discovery platform, Dalton, and announces Sygnature Discovery collaboration
-
Growing improvement in major molecular response (MMR) rates demonstrated with Scemblix vs. all standard-of-care TKIs including imatinib and second generation (2G) TKIs1 Clinically relevant 15.2%...
-
Improved radiographic progression-free survival (rPFS) regardless of disease volume or metastatic presentation achieved with Pluvicto plus standard of care (ARPI + ADT) in PSMAdditionConsistent...
-
Austin, United States, May 28, 2026 (GLOBE NEWSWIRE) -- “The Drug Discovery Market was valued at USD 71.95 billion in 2025 and is projected to surpass USD 174.92 billion by 2035, growing at a CAGR...
-
Fortis Life Sciences launches AbNano® VHH Anti-NK Cell Library, the first NK-cell-derived single-domain antibody library for rapid discovery.
-
The Logical Qubit Pathway Strategy Intends to Integrate the Company’s’ Error Correction Transformer to Reach Modular Infrastructure Tel Aviv, Israel, May 28, 2026 (GLOBE NEWSWIRE) -- Quantum X...
-
Bonito Biosciences and DaltonTx Announce AI-Driven Collaboration to Advance Precision Delivery for Oligotherapeutics
-
Dublin, May 25, 2026 (GLOBE NEWSWIRE) -- The "Biosimulation Market Opportunity, Growth Drivers, Industry Trend Analysis, and Forecast 2026-2035" has been added to ResearchAndMarkets.com's offering....
-
Dublin, May 21, 2026 (GLOBE NEWSWIRE) -- The "Advanced Pharmacovigilance Auditing and Inspections (Sept 3rd - Sept 4th, 2026)" training has been added to ResearchAndMarkets.com's offering. This...
-
More durable, deeper PSA response in patients treated with Pluvicto plus standard of care (ARPI + ADT) vs. SoC aloneDeep PSA reduction higher in patients receiving Pluvicto combination vs. SoC at 12,...